Published in Nature on January 11, 1990
In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy. Science (2015) 4.18
Systemic delivery of antisense oligoribonucleotide restores dystrophin expression in body-wide skeletal muscles. Proc Natl Acad Sci U S A (2004) 3.34
Animal models for muscular dystrophy show different patterns of sarcolemmal disruption. J Cell Biol (1997) 3.32
Dystrophins carrying spectrin-like repeats 16 and 17 anchor nNOS to the sarcolemma and enhance exercise performance in a mouse model of muscular dystrophy. J Clin Invest (2009) 2.89
Adeno-associated virus vector carrying human minidystrophin genes effectively ameliorates muscular dystrophy in mdx mouse model. Proc Natl Acad Sci U S A (2000) 2.83
Exploring the molecular basis for variability among patients with Becker muscular dystrophy: dystrophin gene and protein studies. Am J Hum Genet (1991) 2.79
Antisense-induced exon skipping and synthesis of dystrophin in the mdx mouse. Proc Natl Acad Sci U S A (2001) 2.71
Mechanical function of dystrophin in muscle cells. J Cell Biol (1995) 2.67
Dynamics of single mRNP nucleocytoplasmic transport and export through the nuclear pore in living cells. Nat Cell Biol (2010) 2.59
Adenovirus as an expression vector in muscle cells in vivo. Proc Natl Acad Sci U S A (1992) 2.30
Efficient in vivo gene expression by trans-splicing adeno-associated viral vectors. Nat Biotechnol (2005) 2.16
Adeno-associated virus-mediated microdystrophin expression protects young mdx muscle from contraction-induced injury. Mol Ther (2005) 2.08
Effective rescue of dystrophin improves cardiac function in dystrophin-deficient mice by a modified morpholino oligomer. Proc Natl Acad Sci U S A (2008) 2.06
Current status of pharmaceutical and genetic therapeutic approaches to treat DMD. Mol Ther (2011) 2.06
Forced expression of dystrophin deletion constructs reveals structure-function correlations. J Cell Biol (1996) 1.79
Antisense-mediated exon skipping: a versatile tool with therapeutic and research applications. RNA (2007) 1.78
Octa-guanidine morpholino restores dystrophin expression in cardiac and skeletal muscles and ameliorates pathology in dystrophic mdx mice. Mol Ther (2009) 1.76
A new model for the interaction of dystrophin with F-actin. J Cell Biol (1996) 1.66
Heterogeneity of dystrophin expression in patients with Duchenne and Becker muscular dystrophy. Acta Neuropathol (1990) 1.52
Antisense-induced multiexon skipping for Duchenne muscular dystrophy makes more sense. Am J Hum Genet (2003) 1.52
Chronic systemic therapy with low-dose morpholino oligomers ameliorates the pathology and normalizes locomotor behavior in mdx mice. Mol Ther (2010) 1.48
Point mutations in the dystrophin gene. Proc Natl Acad Sci U S A (1992) 1.46
Exon skipping and translation in patients with frameshift deletions in the dystrophin gene. Am J Hum Genet (1993) 1.40
Cardiac expression of a mini-dystrophin that normalizes skeletal muscle force only partially restores heart function in aged Mdx mice. Mol Ther (2008) 1.36
Preservation of muscle force in Mdx3cv mice correlates with low-level expression of a near full-length dystrophin protein. Am J Pathol (2008) 1.33
Use of epitope libraries to identify exon-specific monoclonal antibodies for characterization of altered dystrophins in muscular dystrophy. Am J Hum Genet (1993) 1.33
Pip5 transduction peptides direct high efficiency oligonucleotide-mediated dystrophin exon skipping in heart and phenotypic correction in mdx mice. Mol Ther (2011) 1.32
Therapeutic approaches to muscular dystrophy. Hum Mol Genet (2011) 1.30
Animal models of Duchenne muscular dystrophy: from basic mechanisms to gene therapy. Dis Model Mech (2015) 1.30
Emerging strategies for cell and gene therapy of the muscular dystrophies. Expert Rev Mol Med (2009) 1.29
Extensive but coordinated reorganization of the membrane skeleton in myofibers of dystrophic (mdx) mice. J Cell Biol (1999) 1.27
Viral-mediated gene therapy for the muscular dystrophies: successes, limitations and recent advances. Biochim Biophys Acta (2006) 1.25
One-year treatment of morpholino antisense oligomer improves skeletal and cardiac muscle functions in dystrophic mdx mice. Mol Ther (2010) 1.25
A phase 1/2a follistatin gene therapy trial for becker muscular dystrophy. Mol Ther (2014) 1.22
Gene therapy of mdx mice with large truncated dystrophins generated by recombination using rAAV6. Mol Ther (2010) 1.21
Emerging genetic therapies to treat Duchenne muscular dystrophy. Curr Opin Neurol (2009) 1.20
Physiological characterization of muscle strength with variable levels of dystrophin restoration in mdx mice following local antisense therapy. Mol Ther (2010) 1.20
Optimizing exon skipping therapies for DMD. Acta Myol (2007) 1.17
Gene therapy for muscular dystrophy: lessons learned and path forward. Neurosci Lett (2012) 1.16
Gene and cell-mediated therapies for muscular dystrophy. Muscle Nerve (2013) 1.14
Rapid mapping by transposon mutagenesis of epitopes on the muscular dystrophy protein, dystrophin. Nucleic Acids Res (1991) 1.14
CRISPR-mediated Genome Editing Restores Dystrophin Expression and Function in mdx Mice. Mol Ther (2015) 1.14
Microdystrophin ameliorates muscular dystrophy in the canine model of duchenne muscular dystrophy. Mol Ther (2013) 1.13
Monoclonal antibodies for dystrophin analysis. Epitope mapping and improved binding to SDS-treated muscle sections. Biochem J (1992) 1.13
Novel mini-dystrophin gene dual adeno-associated virus vectors restore neuronal nitric oxide synthase expression at the sarcolemma. Hum Gene Ther (2011) 1.13
Emerging drugs for Duchenne muscular dystrophy. Expert Opin Emerg Drugs (2012) 1.11
Functional rescue of dystrophin-deficient mdx mice by a chimeric peptide-PMO. Mol Ther (2010) 1.10
Long-term rescue of dystrophin expression and improvement in muscle pathology and function in dystrophic mdx mice by peptide-conjugated morpholino. Am J Pathol (2012) 1.10
Screening for mutations in the muscle promoter region and for exonic deletions in a series of 115 DMD and BMD patients. J Med Genet (1992) 1.10
Exon skipping and duchenne muscular dystrophy therapy: selection of the most active U1 snRNA antisense able to induce dystrophin exon 51 skipping. Mol Ther (2010) 1.09
AAV-microdystrophin therapy improves cardiac performance in aged female mdx mice. Mol Ther (2011) 1.08
A truncated dystrophin lacking the C-terminal domains is localized at the muscle membrane. Am J Hum Genet (1992) 1.07
Protein trans-splicing as a means for viral vector-mediated in vivo gene therapy. Hum Gene Ther (2008) 1.07
Are cysteine-rich and COOH-terminal domains of dystrophin critical for sarcolemmal localization? J Clin Invest (1992) 1.06
Gene therapy in large animal models of muscular dystrophy. ILAR J (2009) 1.05
Gene therapies that restore dystrophin expression for the treatment of Duchenne muscular dystrophy. Hum Genet (2016) 1.04
Functional protection of dystrophic mouse (mdx) muscles after adenovirus-mediated transfer of a dystrophin minigene. Proc Natl Acad Sci U S A (1996) 1.04
Thyroid hormones and skeletal muscle--new insights and potential implications. Nat Rev Endocrinol (2013) 1.04
A simplified immune suppression scheme leads to persistent micro-dystrophin expression in Duchenne muscular dystrophy dogs. Hum Gene Ther (2011) 1.00
Dual AAV therapy ameliorates exercise-induced muscle injury and functional ischemia in murine models of Duchenne muscular dystrophy. Hum Mol Genet (2013) 0.99
Truncated dystrophins can influence neuromuscular synapse structure. Mol Cell Neurosci (2009) 0.97
Predicted and observed sizes of dystrophin in some patients with gene deletions that disrupt the open reading frame. J Med Genet (1992) 0.96
Immunohistochemical analysis of dystrophin-associated proteins in Becker/Duchenne muscular dystrophy with huge in-frame deletions in the NH2-terminal and rod domains of dystrophin. J Clin Invest (1994) 0.96
Integrated study of 100 patients with Xp21 linked muscular dystrophy using clinical, genetic, immunochemical, and histopathological data. Part 1. Trends across the clinical groups. J Med Genet (1993) 0.96
A Two-amino Acid Mutation Encountered in Duchenne Muscular Dystrophy Decreases Stability of the Rod Domain 23 (R23) Spectrin-like Repeat of Dystrophin. J Biol Chem (2009) 0.95
An intact cysteine-rich domain is required for dystrophin function. J Clin Invest (1992) 0.95
Evolutionary conservation of the dystrophin central rod domain. Biochem J (1992) 0.95
Induction of revertant fibres in the mdx mouse using antisense oligonucleotides. Genet Vaccines Ther (2006) 0.95
Functional significance of dystrophin positive fibres in Duchenne muscular dystrophy. Arch Dis Child (1993) 0.94
Exon 45 skipping through U1-snRNA antisense molecules recovers the Dys-nNOS pathway and muscle differentiation in human DMD myoblasts. Mol Ther (2012) 0.93
Differential stabilities of alternative exon-skipped rod motifs of dystrophin. Biochim Biophys Acta (2009) 0.93
From the smallest virus to the biggest gene: marching towards gene therapy for duchenne muscular dystrophy. Discov Med (2006) 0.92
Integrated study of 100 patients with Xp21 linked muscular dystrophy using clinical, genetic, immunochemical, and histopathological data. Part 2. Correlations within individual patients. J Med Genet (1993) 0.91
Gene therapy for muscular dystrophy: moving the field forward. Pediatr Neurol (2014) 0.91
Becker muscular dystrophy patient with a large intragenic dystrophin deletion: implications for functional minigenes and gene therapy. J Med Genet (1991) 0.90
A novel point mutation (G-1 to T) in a 5' splice donor site of intron 13 of the dystrophin gene results in exon skipping and is responsible for Becker muscular dystrophy. Am J Hum Genet (1994) 0.89
Full-length dystrophin reconstitution with adeno-associated viral vectors. Hum Gene Ther (2014) 0.89
Therapy of Genetic Disorders-Novel Therapies for Duchenne Muscular Dystrophy. Curr Pediatr Rep (2014) 0.89
Targeted skipping of human dystrophin exons in transgenic mouse model systemically for antisense drug development. PLoS One (2011) 0.89
Dystrobrevin increases dystrophin's binding to the dystrophin-glycoprotein complex and provides protection during cardiac stress. J Mol Cell Cardiol (2014) 0.88
Multiple exon skipping strategies to by-pass dystrophin mutations. Neuromuscul Disord (2011) 0.87
Duchenne muscular dystrophy gene therapy in the canine model. Hum Gene Ther Clin Dev (2015) 0.86
Gene Therapy for Duchenne muscular dystrophy. Expert Opin Orphan Drugs (2015) 0.86
Zebrafish models flex their muscles to shed light on muscular dystrophies. Dis Model Mech (2012) 0.86
Integrated study of 100 patients with Xp21 linked muscular dystrophy using clinical, genetic, immunochemical, and histopathological data. Part 3. Differential diagnosis and prognosis. J Med Genet (1993) 0.85
Absence of Dystrophin Disrupts Skeletal Muscle Signaling: Roles of Ca2+, Reactive Oxygen Species, and Nitric Oxide in the Development of Muscular Dystrophy. Physiol Rev (2016) 0.85
Impacts of dystrophin and utrophin domains on actin structural dynamics: implications for therapeutic design. J Mol Biol (2012) 0.84
Gene therapy to treat cardiac arrhythmias. Nat Rev Cardiol (2015) 0.83
Personalized exon skipping strategies to address clustered non-deletion dystrophin mutations. Neuromuscul Disord (2010) 0.83
Muscle structure influences utrophin expression in mdx mice. PLoS Genet (2014) 0.81
Mild deficiency of dystrophin-associated proteins in Becker muscular dystrophy patients having in-frame deletions in the rod domain of dystrophin. Am J Hum Genet (1993) 0.81
Identification of novel, therapy-responsive protein biomarkers in a mouse model of Duchenne muscular dystrophy by aptamer-based serum proteomics. Sci Rep (2015) 0.81
Advances in genetic therapeutic strategies for Duchenne muscular dystrophy. Exp Physiol (2015) 0.81
Recent advances in innovative therapeutic approaches for Duchenne muscular dystrophy: from discovery to clinical trials. Am J Transl Res (2016) 0.80
The dystrophin-associated glycoprotein complex: what parts can you do without? Proc Natl Acad Sci U S A (2000) 0.80
Truncated dystrophins reduce muscle stiffness in the extensor digitorum longus muscle of mdx mice. J Appl Physiol (1985) (2012) 0.80
Dystrophin Gene Replacement and Gene Repair Therapy for Duchenne Muscular Dystrophy in 2016: An Interview. Hum Gene Ther Clin Dev (2016) 0.79
Genetic correction of dystrophin deficiency and skeletal muscle remodeling in adult MDX mouse via transplantation of retroviral producer cells. J Clin Invest (1997) 0.79
DMD Mutations in 576 Dystrophinopathy Families: A Step Forward in Genotype-Phenotype Correlations. PLoS One (2015) 0.79
Linkage relationship of a cloned DNA sequence on the short arm of the X chromosome to Duchenne muscular dystrophy. Nature (1982) 11.57
Linkage analysis of two cloned DNA sequences flanking the Duchenne muscular dystrophy locus on the short arm of the human X chromosome. Nucleic Acids Res (1983) 8.92
A highly polymorphic DNA marker linked to adult polycystic kidney disease on chromosome 16. Nature (1985) 7.34
Data on the distribution of fibre types in thirty-six human muscles. An autopsy study. J Neurol Sci (1973) 6.62
Cloning of a representative genomic library of the human X chromosome after sorting by flow cytometry. Nature (1981) 6.18
Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca2+ channel gene CACNL1A4. Cell (1996) 5.99
Characterization of dystrophin in muscle-biopsy specimens from patients with Duchenne's or Becker's muscular dystrophy. N Engl J Med (1988) 5.84
Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature (1993) 5.81
A novel pantothenate kinase gene (PANK2) is defective in Hallervorden-Spatz syndrome. Nat Genet (2001) 5.34
The implications of using an inappropriate reference gene for real-time reverse transcription PCR data normalization. Anal Biochem (2005) 4.94
Abnormal dendritic spines in fragile X knockout mice: maturation and pruning deficits. Proc Natl Acad Sci U S A (1997) 4.73
Utrophin-dystrophin-deficient mice as a model for Duchenne muscular dystrophy. Cell (1997) 4.38
Analysis of deletions in DNA from patients with Becker and Duchenne muscular dystrophy. Nature (1986) 4.13
Vigabatrin-associated retinal cone system dysfunction: electroretinogram and ophthalmologic findings. Neurology (1998) 4.01
The Duchenne muscular dystrophy gene product is localized in sarcolemma of human skeletal muscle. Nature (1988) 3.85
Paradoxical reactions during tuberculosis treatment in patients with and without HIV co-infection. Thorax (2004) 3.77
Abnormal dendritic spine characteristics in the temporal and visual cortices of patients with fragile-X syndrome: a quantitative examination. Am J Med Genet (2001) 3.77
Genetic mapping of chronic childhood-onset spinal muscular atrophy to chromosome 5q11.2-13.3. Nature (1990) 3.48
The polymerase chain reaction: a new epidemiological tool for investigating cervical human papillomavirus infection. BMJ (1989) 3.43
Report of the committee on the genetic constitution of the X chromosome. Cytogenet Cell Genet (1989) 3.37
Growth, survival, and resistance of the Legionnaires' disease bacterium. Ann Intern Med (1979) 3.36
International SMA consortium meeting. (26-28 June 1992, Bonn, Germany). Neuromuscul Disord (1992) 3.26
S-nitrosothiols signal the ventilatory response to hypoxia. Nature (2001) 3.26
Open access clinic providing HIV-I antibody results on day of testing: the first twelve months. BMJ (1991) 3.17
Prenatal diagnosis and carrier detection of Duchenne muscular dystrophy with closely linked RFLPs. Lancet (1985) 3.08
Report of the Committee on the Genetic Constitution of the X and Y Chromosomes. Cytogenet Cell Genet (1985) 3.07
Human dystrophin expression in mdx mice after intramuscular injection of DNA constructs. Nature (1991) 3.03
A full genome search in multiple sclerosis. Nat Genet (1996) 2.96
Amelioration of the dystrophic phenotype of mdx mice using a truncated utrophin transgene. Nature (1996) 2.95
An autosomal transcript in skeletal muscle with homology to dystrophin. Nature (1989) 2.91
Staging system for clinical AIDS patients. Royal Free/Chelsea and Westminster Hospitals Collaborative Group. Lancet (1995) 2.90
The positions of three restriction fragment length polymorphisms on chromosome 4 relative to known genetic markers. Hum Genet (1984) 2.84
Further studies of gene deletions that cause Duchenne and Becker muscular dystrophies. Genomics (1988) 2.74
Preferential deletion of exons in Duchenne and Becker muscular dystrophies. Nature (1987) 2.67
A population-based study of multiple sclerosis in twins. N Engl J Med (1986) 2.59
Deletions in the survival motor neuron gene on 5q13 in autosomal recessive spinal muscular atrophy. Hum Mol Genet (1995) 2.59
Toward a complete linkage map of the human X chromosome: regional assignment of 16 cloned single-copy DNA sequences employing a panel of somatic cell hybrids. Am J Hum Genet (1984) 2.58
A mutation in the alpha tropomyosin gene TPM3 associated with autosomal dominant nemaline myopathy. Nat Genet (1995) 2.57
A single amino acid substitution in the V1 loop of human immunodeficiency virus type 1 gp120 alters cellular tropism. J Virol (1993) 2.46
The use of linked DNA polymorphisms for genotype prediction in families with Duchenne muscular dystrophy. J Med Genet (1983) 2.45
Dystrophin is localized to the plasma membrane of human skeletal muscle fibers by electron-microscopic cytochemical study. Muscle Nerve (1990) 2.41
Theophylline prescribing, serum concentrations, and toxicity. Lancet (1983) 2.40
PDZ domains: targeting signalling molecules to sub-membranous sites. Bioessays (1997) 2.39
Physical mapping studies on the human X chromosome in the region Xq27-Xqter. Genomics (1987) 2.35
Laboratory control values for CD4 and CD8 T lymphocytes. Implications for HIV-1 diagnosis. Clin Exp Immunol (1992) 2.27
Studies on tetrodotoxin resistant action potentials in denervated skeletal muscle. Acta Physiol Scand (1971) 2.24
Factors affecting survival in patients with the acquired immunodeficiency syndrome. AIDS (1996) 2.22
Cloning, sequence analysis, and expression of genes encoding xylan-degrading enzymes from the thermophile "Caldocellum saccharolyticum". Appl Environ Microbiol (1990) 2.22
The epidemiology of pathogenic mitochondrial DNA mutations. Ann Neurol (2000) 2.20
Inhibition of denervation changes in skeletal muscle by blockers of protein synthesis. J Physiol (1972) 2.19
Loss of mucosal CD4 lymphocytes is an early feature of HIV infection. Clin Exp Immunol (1993) 2.17
Dystrophin expression and somatic reversion in prednisone-treated and untreated Duchenne dystrophy. CIDD Study Group. Neurology (1991) 2.16
Virological response to highly active antiretroviral therapy is unaffected by antituberculosis therapy. J Infect Dis (2006) 2.09
Primary structure of dystrophin-related protein. Nature (1992) 2.09
Effective strategy for prenatal prediction of Duchenne and Becker muscular dystrophy. Lancet (1987) 2.08
Role of mitochondrial DNA mutations in human aging: implications for the central nervous system and muscle. Ann Neurol (1998) 2.08
Epidemiology of cerebral palsy in England and Scotland, 1984-9. Arch Dis Child Fetal Neonatal Ed (1998) 2.01
DNA testing for fragile X syndrome in schools for learning difficulties. Arch Dis Child (1995) 1.98
Instability versus predictability: the molecular diagnosis of myotonic dystrophy. J Med Genet (1992) 1.94
ZZ and TAZ: new putative zinc fingers in dystrophin and other proteins. Trends Biochem Sci (1996) 1.94
Lymphocyte activation in HIV-1 infection. II. Functional defects of CD28- T cells. AIDS (1994) 1.93
Two genetic markers closely linked to adult polycystic kidney disease on chromosome 16. Br Med J (Clin Res Ed) (1986) 1.93
Linkage studies of X-linked recessive spastic paraplegia using DNA probes. Hum Genet (1986) 1.92
Methods of microphotometric assay of succinate dehydrogenase and cytochrome c oxidase activities for use on human skeletal muscle. Histochem J (1990) 1.89
A new DNA marker tightly linked to the fragile X locus (FRAXA). Science (1989) 1.88
Dystrophin in skeletal muscle. I. Western blot analysis using a monoclonal antibody. J Neurol Sci (1989) 1.87
Reasons for modification and discontinuation of antiretrovirals: results from a single treatment centre. AIDS (2001) 1.86
Immunological studies of yeast nuclear RNA polymerases at the subunit level. J Biol Chem (1980) 1.84
A premutation that generates a defect at crossing over explains the inheritance of fragile X mental retardation. Am J Med Genet (1985) 1.83
Tenofovir-associated renal and bone toxicity. HIV Med (2009) 1.82
Somatic reversion/suppression in Duchenne muscular dystrophy (DMD): evidence supporting a frame-restoring mechanism in rare dystrophin-positive fibers. Am J Hum Genet (1992) 1.81
Improved diagnosis of Becker muscular dystrophy by dystrophin testing. Neurology (1989) 1.81
Use of a chromosome 21 cloned DNA probe for the analysis of non-disjunction in Down syndrome. Hum Genet (1984) 1.81
Friedreich ataxia: an overview. J Med Genet (2000) 1.79
Direct interaction between emerin and lamin A. Biochem Biophys Res Commun (2000) 1.77
HHV-6 in AIDS. Lancet (1994) 1.76
Prenatal diagnosis of spinal muscular atrophy by gene deletion analysis. Lancet (1995) 1.75
A microdeletion of less than 250 kb, including the proximal part of the FMR-I gene and the fragile-X site, in a male with the clinical phenotype of fragile-X syndrome. Am J Hum Genet (1992) 1.73
Patterns of exon deletions in Duchenne and Becker muscular dystrophy. Hum Genet (1988) 1.73
Mutation detection in the med and medJ alleles of the sodium channel Scn8a. Unusual splicing due to a minor class AT-AC intron. J Biol Chem (1996) 1.71
Infrared signature of structures associated with the H+(H2O)n (n = 6 to 27) clusters. Science (2004) 1.71
Orthostatic hypotension and the Holmes-Adie syndrome. A study of two patients with afferent baroreceptor block. J Neurol Neurosurg Psychiatry (1971) 1.70
Dysferlin is a plasma membrane protein and is expressed early in human development. Hum Mol Genet (1999) 1.69
Report of the committee on the genetic constitution of the X and Y chromosomes. Cytogenet Cell Genet (1987) 1.68
Skeletal muscle-specific expression of a utrophin transgene rescues utrophin-dystrophin deficient mice. Nat Genet (1998) 1.68
Biochemistry of Oleoresinosis : Monoterpene and Diterpene Biosynthesis in Lodgepole Pine Saplings Infected with Ceratocystis clavigera or Treated with Carbohydrate Elicitors. Plant Physiol (1987) 1.68
Cytomegalovirus (CMV) viraemia detected by polymerase chain reaction identifies a group of HIV-positive patients at high risk of CMV disease. AIDS (1997) 1.68
A new mtDNA mutation showing accumulation with time and restriction to skeletal muscle. Am J Hum Genet (1997) 1.68
Pharmacokinetics and antiretroviral activity of lamivudine alone or when coadministered with zidovudine in human immunodeficiency virus type 1-infected pregnant women and their offspring. J Infect Dis (1998) 1.67
Missense mutation clustering in the survival motor neuron gene: a role for a conserved tyrosine and glycine rich region of the protein in RNA metabolism? Hum Mol Genet (1997) 1.67
Further observations on the pathological responses of rat skeletal muscle to toxins isolated from the venom of the Australian tiger snake, Notechis scutatus scutatus. Clin Exp Pharmacol Physiol (1979) 1.66
Posthumous diagnosis of long QT syndrome from neonatal screening cards. Heart Rhythm (2010) 1.65